Abstract
The targeted delivery of genes whose products arrest the cell cycle and/or induce apoptosis represent an important tool for the understanding and controlling forms of unregulated cell growth. The vpr gene product of HIV-1 has been reported to interfere with cell growth and induce apoptosis, but the mechanism of its action is not clearly understood. In order to study these important properties of Vpr, we created a recombinant adenovirus H5.010CMV-vpr (adCMV-vpr) as a tool to deliver the vpr gene to various cell lines to examine its biology. Vpr protein expression was confirmed by Western blot analysis in adCMV-vpr infected cells. We tested the effects of adCMV-vpr on cell growth of several tumor cell lines. Infection of both p53 positive and p53 deficient tumor cell lines with adCMV-vpr resulted in dramatic induction of cell death in short-term assays. We observed that apoptosis was induced through the mitochondrial pathway as we observed changes in the cytochrome c content accompanied by caspase 9 activation. As Bcl-2 is reported to interfere with apoptosis through the mitochondrial pathway, we examined the effect of adCMV-vpr in Bcl-2 over expressing cell lines. We observed that Bcl-2 overexpression does not inhibit adCMV-vpr induced apoptosis. The properties of adCMV-vpr inducing apoptosis through caspase 9 in a p53 pathway independent manner suggest that this is an important reagent. Such a vector may give insight into approaches designed to limit the growth of pathogenic human cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Athanasopoulos T, Fabb S, Dickson G . 2000 Int. J. Mol. Med. 6: 363–375
Ayyavoo V, Mahboubi A, Mahalingam S, Ramalingam R, Kudchodkar S, Williams WV, Green DR, Weiner DB . 1997 Nat. Med. 3: 1117–1123
Bonnet MC, Tartaglia J, Verdier F, Kourilsky P, Lindberg A, Klein M, Moingeon P . 2000 Immunol. Lett. 74: 11–25
Bridge E, Ketner G . 1989 J. Virol. 63: 631–638
Boon B, Grovit-Ferbas K, Stewart SA, Chen ISY . 1998 Science 281: 266–269
Bridge E, Ketner G . 1990 Virology 174: 345–353
Brooks LA, Tidy JA, Gusterson B, Hiller L, O'Nions J, Gasco M, Marin MC, Farrell PJ, Kaelin Jr WG, Crook T . 2000 Cancer Res. 60: 6875–6877
Cohen EA, Dehni G, Sodroski JG, Haseltine WA . 1990 J. Virol. 64: 3097–3099
Davis AR, Meyers K, Wilson JM . 1998 Gene Therapy 5: 1148–1152
Finkel E . 2001 Science 292: 624–626
Gilboa E . 1999 Immunity 11: 263–270
Goh WC, Rogel ME, Kinsey CM, Michael SF, Fultz PN, Nowak MA, Hahn BH, Emerman M . 1998 Nat. Med. 4: 65–71
Fisher KJ, Choi H, Burda J, Chen SJ, Wilson JM . 1996 Virology 217: 11–22
Jacotot E, Ferri KF, Hamel C, Brenner C, Druillennec S, Hoebeke J, Rustin P, Metivier D, Lenoir C, Geuskens M, Vieria HL, Loeffler M, Belzacq AS, Briand JP, Zamzami N, Edelman L, Xie ZH, Reed JC, Roques BP, Kroemer G . 2001 J. Exp. Med. 193: 509–519
Jolly D . 1994 Cancer Gene Ther. Mar. 1: 51–64
Hanahan D, Weinberg RA . 2000 Cell 100: 57–70
He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR . 1995 J. Virol. 69: 6705–6711
Hrimech M, Yao XJ, Bachand F, Rougeau N, Cohen EA . 1999 J. Virol. 73: 4101–4109
Kharbanda S, Pandey P, Schofield L, Israels S, Roncinske R, Yoshida K, Bharti A, Yuan ZM, Saxena S, Weichselbaum R, Nalin C, Kufe D . 1997 Proc. Natl. Acad. Sci. USA 94: 6939–6942
Komata T, Kondo Y, Koga S, Ko SC, Chung LW, Kondo S . 2000 Gene Therapy 7: 2071–2079
Kunke D, Grimm D, Denger S, Kreuzer J, Delius H, Komitowski D, Kleinschmidt JA . 2000 Cancer Gene Ther. 7: 766–777
Levy DN, Fernandes LS, Williams WV, Weiner DB . 1993 Cell 72: 541–550
Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X . 1997 Cell 91: 479–489
Lynch CM, Hara PS, Leonard JC, Williams JK, Dean RH, Geary RL . 1997 Circ. Res. 80: 497–505
Mahalingam S, MacDonald B, Ugen KE, Ayyavoo V, Agadjanyan MG, Williams WV, Weiner DB . 1997 DNA Cell Biol. 16: 137–143
May E, Jenkins JR, May P . 1991 Oncogene 6: 1363–1365
Mittereder N, March KL, Trapnell BC . 1996 J. Virol. 70: 7498–7509
Miyake S, Makimura M, Kanegae Y, Harada S, Sato Y, Takamori K, Tokuda C, Saito I . 1996 Proc. Natl. Acad. Sci. USA 93: 1320–1324
Muthumani K, Kudchodkar S, Papasavvas E, Montaner LJ, Weiner DB, Ayyavoo V . 2000a J. Leukoc. Biol. 68: 366–372
Muthumani K, Montaner LJ, Ayyavoo V, Weiner DB . 2000b DNA Cell Biol. 19: 179–188
Newbold R . 1984 Nature 310: 628–629
Patel CA, Mukhtar M, Pomerantz RJ . 2000 J. Virol. 74: 9717–9726
Perkus ME, Tartaglia J, Paoletti E . 1995 J. Leukoc. Biol. 58: 1–13
Planchon SM, Wuerzberger S, Frydman B, Witiak DT, Hutson P, Church DR, Wilding G, Boothman DA . 1995 Cancer Res. 55: 3706–3711
Rountree MR, Bachman KE, Herman JG, Baylin SB . 2001 Oncogene 20: 3156–3165
Rozenszajn LA, Firestein F, Ashush H, Elimelech R, Barda-Saad M, Radnay J, Shemesh L, Rosenschein U . 2000 Exp. Hematol. 28: 1503–1507
Sefton BM, Trowbridge IS, Cooper JA, Scolnick EM . 1982 Cell 31: 465–474
Sawaya BE, Khalili K, Mercer WE, Denisova L, Amini S . 1998 J. Biol. Chem. 273: 20052–20057
Sawada H, Wakabayashi H, Nawa A, Mora E, Cavanaugh PG, Nicolson GL . 1996 Clin. Exp. Metastasis 14: 308–313
Shostak LD, Ludlow J, Fisk J, Pursell S, Rimel BJ, Nguyen D, Rosenblatt JD, Planelles V . 1999 Exp. Cell Res. 251: 156–165
Stewart SA, Poon B, Song JY, Chen IS . 2000 J. Virol. 74: 3105–3111
Stewart SA, Poon B, Jowett JB, Xie Y, Chen IS . 1999 Proc. Natl. Acad. Sci. USA 96: 12039–12043
Stirewalt DL, Radich JP . 2000 Hematol. 5: 15–25
Subbramanian RA, Yao XJ, Dilhuydy H, Rougeau N, Bergeron D, Robitaille Y, Cohen EA . 1998 J. Mol. Biol. 278: 13–30
Toma S, Isnardi L, Raffo P, Riccardi L, Dastoli G, Apfel C, LeMotte P, Bollag W . 1998 Int. J. Cancer 78: 86–94
Qi V, Weinrib L, Ma N, Li JH, Klamut H, Liu FF . 2001 Int. J. Hyperthermia 17: 38–47
Qazilbash MH, Xiao X, Seth P, Cowan KH, Walsh CE . 1997 Gene Ther. 4: 675–682
Vincent KA, Piraino ST, Wadsworth SC . 1997 J. Virol. 71: 1897–1905
Valenzuela MT, Mateos S, Ruiz de Almodovar JM, McMillan TJ . 2000 Radiother. Oncol. 54: 261–271
Wyllie A . 1997 Nature 389: 237–238
Wigler MH . 1990 Nature 346: 696–697
Acknowledgements
This work was supported in parts by Seed project grants from the Institute of Human Gene Therapy, UPENN and NIH grants to DB Weiner.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Muthumani, K., Zhang, D., Hwang, D. et al. Adenovirus encoding HIV-1 Vpr activates caspase 9 and induces apoptotic cell death in both p53 positive and negative human tumor cell lines. Oncogene 21, 4613–4625 (2002). https://doi.org/10.1038/sj.onc.1205549
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205549
Keywords
This article is cited by
-
Stress proteins: the biological functions in virus infection, present and challenges for target-based antiviral drug development
Signal Transduction and Targeted Therapy (2020)
-
HIV-1 viral protein R downregulates Ebp1 and stabilizes p53 in glioblastoma U87MG cells
Clinical and Translational Oncology (2014)
-
HIV-1 Accessory Protein Vpr: Relevance in the pathogenesis of HIV and potential for therapeutic intervention
Retrovirology (2011)
-
Combined Antitumor Effect of Ad-bFGF-siRNA and Ad-Vpr on the Growth of Xenograft Glioma in Nude Mouse Model
Pathology & Oncology Research (2011)
-
Vpr-Host Interactions During HIV-1 Viral Life Cycle
Journal of Neuroimmune Pharmacology (2011)